COMPANY PROFILE
| Price and Volume | |
|---|---|
| Recent Price | 14.23 |
| 52 Week High | 27.00 |
| 52 Week Low | 9.15 |
| Avg. Daily Vol. (Mil) | 0.30 |
| Beta (3 year) | -0.64 |
| Share Related Items | |
| Mkt Cap (Mil) | 438.27 |
| Shares Out (Mil) | 30.80 |
| Float (Mil) | 17.13 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.70 |
| Current Ratio | 3.40 |
| LT Debt/ Equity | 0.09 |
| Total Debt / Equity | 0.17 |
| Valuation Ratios | |
| Price Earnings | 15.80 |
| Price/Sales | 2.02 |
| Price/Book | 1.86 |
| Price/Cash Flow | 14.20 |
| Per Share Data | |
| Earnings | 0.90 |
| Sales | 7.04 |
| Book Value | 7.64 |
| Cash Flow | 1.00 |
| Business Summary | |
|---|---|
| A biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the bodys immune system to prevent or treat disease. | |
| General Information | |
| 2273 Research Boulevard
Suite 400 Rockville, MD 20850 |
|
| 1.0 | |
| http://www.emergentbiosolutions.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 587 | |
| CEO: Fuad El-Hibri | |
| Short Interest | |
| Current Month (Mil) | 1.03 |
| Previous Month (Mil) | 0.89 |
| Short Interest Ratio (Days) | 2.60 |
| Management Effectiveness | |
| Return on Equity | 11.00 |
| Return on Assets | 8.20 |
| Return on Investments | 10.10 |
| Profitability | |
| Gross Margin | 83.30 |
| EBIT Margin | 16.50 |
| Profit Margin | 11.90 |